{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:26:44Z","timestamp":1791404804877,"version":"4.3.3"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by absolute monocytosis, one or more lineage dysplasia, and proliferative features including myeloid hyperplasia, splenomegaly, and constitutional symptoms. Because of vast clinical heterogeneity in presentation and course, risk stratification is used for a risk-adapted treatment strategy. Numerous prognostic scoring systems exist, some of which incorporate mutational information. Treatment ranges from observation to allogeneic hematopoietic stem cell transplantation. Therapies include hydroxyurea for cytoreduction, hypomethylating agents, and the JAK1\/2 inhibitor ruxolitinib to address splenomegaly and constitutional symptoms. Recently, oral decitabine with cedazuridine was approved and represents a convenient treatment option for CMML patients. Although novel therapeutics are in development for CMML, further work is needed to elucidate possible targets unique to the CMML clone. In this review, we will detail the pathophysiology, risk stratification, available treatment modalities, and novel therapies for CMML, and propose a modern treatment algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Chronic myelomonocytic leukemia (CMML) is a clinically heterogenous disease, which poses significant management challenges. The diagnosis of CMML requires bone marrow biopsy and aspirate with thorough evaluation. Risk stratification and symptom assessment are essential to designing an effective treatment plan, which may include hypomethylating agents (HMAs) in intermediate or high-risk patients. The recently approved oral decitabine\/cedazuridine provides a convenient alternative to parenteral HMAs. Ruxolitinib may be effective in ameliorating proliferative symptoms and splenomegaly. Allogeneic stem cell transplantation remains the only treatment with curative potential; however, novel therapies are in clinical development which may significantly alter the therapeutic landscape of CMML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13769","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T05:33:24Z","timestamp":1617255204000},"page":"406-421","source":"Crossref","is-referenced-by-count":14,"title":["Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia"],"prefix":"10.1093","volume":"26","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Rippel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Feld","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"El Jamal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"2021122511543634500_onco13769-bib-0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0002","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML-Dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leukemia Res"},{"key":"2021122511543634500_onco13769-bib-0003","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.23962","article-title":"Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0004","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0005","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and prevalence of myelodysplastic syndromes: Data from the D\u00fcsseldorf MDS-registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leukemia Res"},{"key":"2021122511543634500_onco13769-bib-0006","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0007","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1002\/cncr.30814","article-title":"Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study","volume":"123","author":"Zeidan","year":"2017","journal-title":"Cancer"},{"key":"2021122511543634500_onco13769-bib-0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11864-018-0581-6","article-title":"Current management and recent advances in the treatment of chronic myelomonocytic leukemia","volume":"19","author":"Hunter","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"2021122511543634500_onco13769-bib-0009","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2021122511543634500_onco13769-bib-0010","doi-asserted-by":"crossref","first-page":"95.e1","DOI":"10.1016\/j.bbmt.2020.10.007","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia","volume":"27","author":"Gagelmann","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2021122511543634500_onco13769-bib-0011","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41379-019-0215-y","article-title":"Update on the pathologic diagnosis of chronic myelomonocytic leukemia","volume":"32","author":"Arber","year":"2019","journal-title":"Mod Pathol"},{"key":"2021122511543634500_onco13769-bib-0012","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"International Working Group on Morphology of Myelodysplastic Syndrome. Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"key":"2021122511543634500_onco13769-bib-0013","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"2021122511543634500_onco13769-bib-0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ejh.12512","article-title":"Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes","volume":"95","author":"Schemenau","year":"2015","journal-title":"Eur J Haematol"},{"key":"2021122511543634500_onco13769-bib-0015","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0016","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1309\/HRJ1XKTD77J1UTFM","article-title":"Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis","volume":"124","author":"Xu","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"2021122511543634500_onco13769-bib-0017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1309\/AJCPUY0ZMG3VTLFG","article-title":"Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with Cd11c underexpression","volume":"140","author":"Sojitra","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2021122511543634500_onco13769-bib-0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"key":"2021122511543634500_onco13769-bib-0019","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in polycythemia vera: Clinical and molecular correlates","volume":"92","author":"Barraco","year":"2017","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.15061","article-title":"Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br J Haematol"},{"key":"2021122511543634500_onco13769-bib-0021","doi-asserted-by":"crossref","first-page":"103274","DOI":"10.18632\/oncotarget.21870","article-title":"Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression","volume":"8","author":"Petrova-Drus","year":"2017","journal-title":"Oncotarget"},{"key":"2021122511543634500_onco13769-bib-0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2021122511543634500_onco13769-bib-0023","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00277-018-3289-6","article-title":"Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"key":"2021122511543634500_onco13769-bib-0024","doi-asserted-by":"crossref","first-page":"101137","DOI":"10.1016\/j.beha.2019.101137","article-title":"Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management","volume":"33","author":"Valent","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122511543634500_onco13769-bib-0025","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"key":"2021122511543634500_onco13769-bib-0026","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","article-title":"A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0027","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0028","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3324\/haematol.2018.208488","article-title":"Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia","volume":"105","author":"Beke","year":"2020","journal-title":"Haematologica"},{"key":"2021122511543634500_onco13769-bib-0029","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood-2016-07-692988","article-title":"When clinical heterogeneity exceeds genetic heterogeneity: Thinking outside the genomic box in chronic myelomonocytic leukemia","volume":"128","author":"Ball","year":"2016","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0030","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0031","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J"},{"key":"2021122511543634500_onco13769-bib-0033","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0034","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2af35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0035","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0036","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0037","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.10108","article-title":"Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes","volume":"70","author":"Boudard","year":"2002","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0039","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.leu.2402220","article-title":"Prognostic evaluation of the microvascular network in myelodysplastic syndromes","volume":"15","author":"Korkolopoulou","year":"2001","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0040","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0041","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","article-title":"Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia","volume":"58","author":"Zahid","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021122511543634500_onco13769-bib-0042","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"key":"2021122511543634500_onco13769-bib-0043","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0044","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0045","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1182\/bloodadvances.2020002415","article-title":"Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia","volume":"4","author":"Mangaonkar","year":"2020","journal-title":"Blood Adv"},{"key":"2021122511543634500_onco13769-bib-0046","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-american-british (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"2021122511543634500_onco13769-bib-0047","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122511543634500_onco13769-bib-0048","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","article-title":"Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories","volume":"2","author":"Loghavi","year":"2018","journal-title":"Blood Adv"},{"key":"2021122511543634500_onco13769-bib-0049","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","article-title":"Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes","volume":"8","author":"Gelsi-Boyer","year":"2008","journal-title":"BMC Cancer"},{"key":"2021122511543634500_onco13769-bib-0050","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"2021122511543634500_onco13769-bib-0051","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0052","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: A Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0053","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"2021122511543634500_onco13769-bib-0054","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"2021122511543634500_onco13769-bib-0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"BrJ Haematol"},{"key":"2021122511543634500_onco13769-bib-0056","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-A study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0057","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0058","volume-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. Center for International Blood and Marrow Transplant Research","author":"Phelan","year":"2020"},{"key":"2021122511543634500_onco13769-bib-0059","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the european group for blood and marrow transplantation (EBMT)","volume":"118","author":"Kroger","year":"2002","journal-title":"Br J Hematol"},{"key":"2021122511543634500_onco13769-bib-0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic haematopoietic sct for chronic myelomonocytic leukaemia: A single-centre experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2021122511543634500_onco13769-bib-0061","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2021122511543634500_onco13769-bib-0062","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: Relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122511543634500_onco13769-bib-0063","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","article-title":"Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"key":"2021122511543634500_onco13769-bib-0064","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.15707","article-title":"Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: A systematic literature review","volume":"184","author":"Park","year":"2019","journal-title":"Br J Haematol"},{"key":"2021122511543634500_onco13769-bib-0066","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ejh.12679","article-title":"Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia","volume":"97","author":"Xicoy","year":"2016","journal-title":"Eur J Haematol"},{"key":"2021122511543634500_onco13769-bib-0067","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0068","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0069","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"2021122511543634500_onco13769-bib-0070","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: A retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol"},{"key":"2021122511543634500_onco13769-bib-0071","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Onco"},{"key":"2021122511543634500_onco13769-bib-0072","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"2021122511543634500_onco13769-bib-0073","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"2021122511543634500_onco13769-bib-0074","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"2021122511543634500_onco13769-bib-0075","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"2021122511543634500_onco13769-bib-0076","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0077","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-azacitidine: A case series and literature review","volume":"36","author":"Thorpe","year":"2012","journal-title":"Leuk Res"},{"key":"2021122511543634500_onco13769-bib-0078","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"key":"2021122511543634500_onco13769-bib-0079","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2021122511543634500_onco13769-bib-0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10428194.2012.719617","article-title":"High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: Results of an Italian retrospective study","volume":"54","author":"Fianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2021122511543634500_onco13769-bib-0081","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk Res"},{"key":"2021122511543634500_onco13769-bib-0082","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0083","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0084","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2021122511543634500_onco13769-bib-0085","doi-asserted-by":"crossref","first-page":"1717a","DOI":"10.1182\/blood-2019-131071","article-title":"WHO-defined chronic myelomonocytic leukemia-2 (CMML-2) patients rapidly progress to aml suggesting this entity represents a transitory clinical state","volume":"134","author":"Hunter","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"2021122511543634500_onco13769-bib-0086","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine versus hydroxyurea for advanced proliferative CMML: Results of the Emsco randomized phase 3 dacota trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0087","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122511543634500_onco13769-bib-0088","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0089","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0090","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/10428194.2017.1369070","article-title":"A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1","volume":"59","author":"Burgstaller","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2021122511543634500_onco13769-bib-0091","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0092","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/0006-2952(73)90137-8","article-title":"Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase","volume":"22","author":"Chabner","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"2021122511543634500_onco13769-bib-0093","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2011-08-371690","article-title":"Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine","volume":"119","author":"Lavelle","year":"2012","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0094","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0095","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0096","first-page":"3047","article-title":"A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer","volume":"10","author":"Sohal","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2021122511543634500_onco13769-bib-0097","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V122.21.2526.2526","article-title":"Preclinical data in cynomolgus (cyn) monkeys of ASTX727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel cytidine deaminase inhibitor (CDAi) E7727","volume":"122","author":"Oganesian","year":"2013","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0098","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0099","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: A multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol"},{"key":"2021122511543634500_onco13769-bib-0100","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: A phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"2021122511543634500_onco13769-bib-0101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-133855","article-title":"Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)","volume":"136","author":"Savona","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"2021122511543634500_onco13769-bib-0102","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0103","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511543634500_onco13769-bib-0104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511543634500_onco13769-bib-0105","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2021122511543634500_onco13769-bib-0106","first-page":"162","article-title":"Promising results of a phase 1\/2 clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia","volume":"130","author":"Padron","year":"2017","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0107","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"key":"2021122511543634500_onco13769-bib-0108","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.2019004352","article-title":"Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia","volume":"136","author":"Patnaik","year":"2020","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0109","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","article-title":"Targeting the ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?","volume":"96","author":"Reuter","year":"2000","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0110","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"2021122511543634500_onco13769-bib-0111","first-page":"2963","article-title":"Preliminary results from an open-label, phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML)","volume":"130","author":"Patnaik","year":"2017","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0112","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2559.2012.04175.x","article-title":"The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias","volume":"60","author":"Rollins-Raval","year":"2012","journal-title":"Histopathology"},{"key":"2021122511543634500_onco13769-bib-0113","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2021122511543634500_onco13769-bib-0114","doi-asserted-by":"crossref","first-page":"7059a","DOI":"10.1200\/JCO.2019.37.15_suppl.7059","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML)","volume":"37","author":"Patnaik","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0115","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-09-1048","article-title":"S110, a 5-Aza-2\u2032-deoxycytidine\u2013containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth","volume":"9","author":"Chuang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122511543634500_onco13769-bib-0116","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511543634500_onco13769-bib-0117","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: Phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol"},{"key":"2021122511543634500_onco13769-bib-0118","volume-title":"Astex and Otsuka announce results of phase 3 ASTRAL-2 and ASTRAL-3 studies of guadecitabine (SGI-110) in patients with previously treated acute myeloid leukemia (AML) and myelodysplastic syndromes or chronic myelomonocytic leukemia (MDS\/CMML). Available at","author":"Astex Pharmaceuticals"},{"key":"2021122511543634500_onco13769-bib-0119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1389203043379783","article-title":"Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system","volume":"5","author":"Chiba","year":"2004","journal-title":"Curr Protein Pept Sci"},{"key":"2021122511543634500_onco13769-bib-0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol Cell"},{"key":"2021122511543634500_onco13769-bib-0121","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2021122511543634500_onco13769-bib-0122","doi-asserted-by":"crossref","first-page":"7506a","DOI":"10.1200\/JCO.2020.38.15_suppl.7506","article-title":"Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (PTS) with higher-risk myelodysplastic syndromes (MDS)\/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777)","volume":"38","author":"Ades","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511543634500_onco13769-bib-0123","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2021122511543634500_onco13769-bib-0124","doi-asserted-by":"crossref","volume-title":"Initial results of a phase I\/II study of venetoclax in combination with azacitidine in treatment-naive and relapsed\/refractory high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML): ASH Annual Meeting, December 5\u20138, 2020; Virtual; 1289","author":"Morita","DOI":"10.1182\/blood-2020-140644"},{"key":"2021122511543634500_onco13769-bib-0125","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2021122511543634500_onco13769-bib-0127","doi-asserted-by":"crossref","first-page":"673a","DOI":"10.1182\/blood-2019-123854","article-title":"Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML)","volume":"134","author":"Steensma","year":"2019","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0128","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"2021122511543634500_onco13769-bib-0129","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2021122511543634500_onco13769-bib-0130","doi-asserted-by":"crossref","first-page":"465a","DOI":"10.1182\/blood-2018-99-119424","article-title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2021122511543634500_onco13769-bib-0131","doi-asserted-by":"crossref","first-page":"466a","DOI":"10.1182\/blood-2018-99-118577","article-title":"PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: An initial safety and efficacy analysis","volume":"132","author":"Gerds","year":"2018","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0132","volume-title":"The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: Phase 1b results: EHA Annual Meeting; November 19\u201321, 2020; Virtual; S187","author":"Sallman"},{"issue":"1","key":"2021122511543634500_onco13769-bib-0133","doi-asserted-by":"crossref","first-page":"3109a","DOI":"10.1182\/blood-2018-99-120184","article-title":"Leukocytosis is associated with end organ damage in chronic myelomonocytic leukemia (CMML) and can be mitigated with cytoreductive therapy","volume":"132","author":"Hunter","year":"2018","journal-title":"Blood"},{"key":"2021122511543634500_onco13769-bib-0134","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/1078-0432.CCR-16-0372","article-title":"Unplugging JAK\/STAT in chronic myelomonocytic leukemia","volume":"22","author":"Solary","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122511543634500_onco13769-bib-0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","article-title":"Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML","volume":"33","author":"Niyongere","year":"2019","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13769","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13769","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/406\/41923473\/oncolo_26_5_406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/406\/41923473\/oncolo_26_5_406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:57:03Z","timestamp":1640433423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/5\/406\/6445668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":135,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,21]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13769","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,4,21]]}}}